Form 4: RenovoRx CEO Shaun Bagai Awarded Over 100,000 Stock Options

RenovoRx, Inc. CEO Shaun Bagai has been granted 102,498 stock options, vesting over four years, following stockholder approval of an increase in the company's equity incentive plan.

Summary

• Shaun Bagai, RenovoRx, Inc.'s Director and Chief Executive Officer, was awarded 102,498 stock options.
• The award consists of 21,072 incentive stock options and 81,426 non-qualified options.
• These options were granted under the Issuer's Amended and Restated 2021 Omnibus Equity Incentive Plan.
• The Compensation Committee of the Board of Directors approved the award on July 1, 2025.
• The issuance was contingent on the availability of shares under the Plan, which became effective after stockholder approval of an increase in the shares reserve at the annual meeting on June 24, 2025.
• The options have an exercise price of $1.27.
• Vesting occurs over four years at a rate of 1/48 per month, with no cliff, commencing on January 1, 2025.
• The options will be fully vested by January 1, 2029, and will expire on July 1, 2035.
• Exercisability is contingent upon an effective registration statement covering the underlying shares.

Sentiment

Score: 6

Explanation: The award of stock options to the CEO is a standard practice for executive compensation, aligning management incentives with shareholder interests. The stockholder approval of the plan increase is a positive governance sign. The contingency on a registration statement is a minor point but not inherently negative.

Positives

• The award of 102,498 stock options to CEO Shaun Bagai aligns management's interests with shareholder value creation.
• The approval of the increased share reserve by stockholders demonstrates support for the company's equity incentive plan.

Negatives

• No direct negatives are apparent from this Form 4 filing, which primarily reports an equity award.

Risks

• The exercisability of the options is contingent upon an effective registration statement covering the underlying shares, which could delay or prevent exercise if not met.

Future Outlook

The awarded stock options will vest over four years, commencing January 1, 2025, and will be fully vested by January 1, 2029, expiring on July 1, 2035. Their exercisability is conditional on an effective registration statement covering the underlying shares.

Industry Context

This Form 4 filing reports a routine insider equity award, common practice across industries to incentivize and retain key executives. It does not provide broader industry trends or competitive insights.

Corporate Governance

Related Party Transactions

• The award of 102,498 stock options to Shaun Bagai, the Chief Executive Officer and a Director, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential for minor dilution from the issuance of new shares upon option exercise, but also improved alignment of CEO incentives with long-term shareholder value.
• Employees: The award is part of an equity incentive plan, which generally benefits employees by providing opportunities for ownership and long-term incentives.

Next Steps

• Continued vesting of the 102,498 stock options over the next four years, at a rate of 1/48 per month.
• The company will need to ensure an effective registration statement covers the shares underlying the options for them to become exercisable.

Key Dates

Keywords

RenovoRx, RNXT, Shaun Bagai, stock options, equity incentive plan, Form 4, SEC filing, CEO compensation, beneficial ownership, insider transaction